India PRIP Scheme Second Call
Analysis based on 6 articles · First reported Aug 28, 2026 · Last updated Aug 29, 2026
The second call under the PRIP scheme is expected to boost innovation and R&D investment in India's pharmaceutical and medical technology sectors, potentially benefiting startups and established companies. The government's continued support signals a positive regulatory environment, likely enhancing the competitiveness of Indian pharma and MedTech firms in global markets.
The India — Ministry of Chemicals and Fertilizers, under the India — Ministry of Chemicals and Fertilizers, announced the second call for applications under the Promotion of Research and Innovation in Pharma & MedTech (PRIP) Scheme. The scheme, with a financial outlay of Rs 5,000 crore, aims to strengthen India's pharma and MedTech R&D ecosystem by supporting startups, MSMEs, and large companies. Financial support of up to Rs 5 crore per project is available for early-stage projects (TRL 1-3) and up to Rs 100 crore per project for later-stage projects (TRL 4-6), subject to a 35% co-funding requirement. The application window opens by mid-September. Priority areas include new medicines, complex generics, biosimilars, and novel medical devices such as AI-based diagnostics and robotic surgical tools. The scheme also provides mentorship and facilitates collaboration through initiatives like MedTech Mitra and Patent Mitra.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard